Longitudinal investigation of a xenograft tumor zebrafish model using polarization-sensitive optical coherence tomography.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 09 2022
13 09 2022
Historique:
received:
24
05
2022
accepted:
30
08
2022
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
Breast cancer is a leading cause of death in female patients worldwide. Further research is needed to get a deeper insight into the mechanisms involved in the development of this devastating disease and to find new therapy strategies. The zebrafish is an established animal model, especially in the field of oncology, which has shown to be a promising candidate for pre-clinical research and precision-based medicine. To investigate cancer growth in vivo in zebrafish, one approach is to explore xenograft tumor models. In this article, we present the investigation of a juvenile xenograft zebrafish model using a Jones matrix optical coherence tomography (JM-OCT) prototype. Immunosuppressed wild-type fish at 1-month post-fertilization were injected with human breast cancer cells and control animals with phosphate buffered saline in the tail musculature. In a longitudinal study, the scatter, polarization, and vasculature changes over time were investigated and quantified in control versus tumor injected animals. A significant decrease in birefringence and an increase in scattering signal was detected in tumor injected zebrafish in comparison to the control once. This work shows the potential of JM-OCT as a non-invasive, label-free, three-dimensional, high-resolution, and tissue-specific imaging tool in pre-clinical cancer research based on juvenile zebrafish models.
Identifiants
pubmed: 36100620
doi: 10.1038/s41598-022-19483-z
pii: 10.1038/s41598-022-19483-z
pmc: PMC9470556
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
15381Subventions
Organisme : Austrian Science Fund FWF
ID : Schrödinger grant J4460
Pays : Austria
Organisme : European Research Council
ID : ERC StG 640396 OPTIMALZ
Pays : International
Organisme : NICHD NIH HHS
ID : 1R01HD102616-01A1
Pays : United States
Organisme : Austrian Science Fund FWF
ID : J 4460
Pays : Austria
Organisme : NICHD NIH HHS
ID : R01 HD102616
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Invest Ophthalmol Vis Sci. 2012 May 31;53(6):3126-38
pubmed: 22499984
Skin Res Technol. 2001 Feb;7(1):1-9
pubmed: 11301634
Int J Ayurveda Res. 2010 Oct;1(4):274-8
pubmed: 21455458
Nat Rev Clin Oncol. 2015 Dec;12(12):693-704
pubmed: 26196250
Opt Express. 2008 Oct 13;16(21):16410-22
pubmed: 18852747
Am J Cancer Res. 2015 Sep 15;5(10):2929-43
pubmed: 26693050
Mol Vis. 2008;14:2157-70
pubmed: 19052656
Biomed Opt Express. 2020 Mar 23;11(4):2137-2151
pubmed: 32341872
J Biophotonics. 2009 May;2(5):288-91
pubmed: 19434615
Front Oncol. 2017 Aug 28;7:186
pubmed: 28894696
Biomed Opt Express. 2017 Feb 01;8(3):1290-1305
pubmed: 28663829
Opt Lett. 2014 Dec 15;39(24):6783-6
pubmed: 25502996
J Appl Physiol (1985). 2013 Nov 1;115(9):1393-401
pubmed: 23990241
IEEE J Sel Top Quantum Electron. 2016 Jul-Aug;22(4):
pubmed: 27721647
Animals (Basel). 2020 Dec 09;10(12):
pubmed: 33317187
Cells. 2021 Oct 25;10(11):
pubmed: 34831102
Nat Rev Cancer. 2020 May;20(5):263-273
pubmed: 32251397
Opt Express. 2006 Aug 21;14(17):7821-40
pubmed: 19529151
Microsc Res Tech. 2018 Feb;81(2):153-161
pubmed: 27155205
Curr Opin Biomed Eng. 2017 Dec;4:32-39
pubmed: 29335679
J Biomed Biotechnol. 2012;2012:817341
pubmed: 22701308
Biomed Opt Express. 2022 Mar 17;13(4):2202-2223
pubmed: 35519284
Biotechniques. 2005 Aug;39(2):227-37
pubmed: 16116796
Cell Stem Cell. 2008 Feb 7;2(2):183-9
pubmed: 18371439
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17406-11
pubmed: 17954920
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cells. 2020 Jan 25;9(2):
pubmed: 31991800
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
EBioMedicine. 2019 Sep;47:24-26
pubmed: 31416720
Opt Express. 2006 Feb 20;14(4):1547-56
pubmed: 19503481
Zebrafish. 2010 Sep;7(3):297-304
pubmed: 20807039
J Biomed Opt. 2017 Dec;22(12):1-23
pubmed: 29274145
J Biophotonics. 2013 Sep;6(9):668-78
pubmed: 22961725
J Biomed Opt. 2022 Jan;27(1):
pubmed: 35064657
Biomed Opt Express. 2020 Sep 15;11(10):5618-5632
pubmed: 33149975
Comp Biochem Physiol A Mol Integr Physiol. 2020 Aug;246:110705
pubmed: 32339660
J Biomed Opt. 2016 Dec 1;21(12):126022
pubmed: 28036094
PLoS One. 2021 Mar 5;16(3):e0246504
pubmed: 33667238
Vis Neurosci. 2016 Jan;33:E011
pubmed: 28177275
J Cancer. 2020 May 18;11(15):4474-4494
pubmed: 32489466
PLoS One. 2011;6(11):e27385
pubmed: 22110636
Cancer Treat Rev. 2021 Jul;98:102223
pubmed: 34049187
Opt Express. 2014 Jun 30;22(13):16472-92
pubmed: 24977897
Biology (Basel). 2021 Mar 24;10(4):
pubmed: 33804830
Transl Vis Sci Technol. 2018 Sep 04;7(5):4
pubmed: 30197836
Biomed Opt Express. 2017 Feb 24;8(3):1838-1873
pubmed: 28663869
Trends Cancer. 2020 Jul;6(7):569-579
pubmed: 32312681
Adv Exp Med Biol. 2017;1007:179-197
pubmed: 28840558
Nat Med. 2003 Jun;9(6):685-93
pubmed: 12778167
Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95(1):7-11
pubmed: 21922639
Opt Express. 2010 Jan 18;18(2):854-76
pubmed: 20173907
Biomed Opt Express. 2018 Nov 28;9(12):6519-6528
pubmed: 31065446
Biomed Opt Express. 2015 Sep 11;6(10):3932-40
pubmed: 26504643